Details of the Drug Combination

General Information of Drug Combination (ID: DCY0F38)

Drug Combination Name
Indazole derivative 5 Hepzato
Indication
Disease Entry Status REF
Amelanotic melanoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Hepzato   DM2AZPP
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: M14
Zero Interaction Potency (ZIP) Score: 2.88
Bliss Independence Score: 5.14
Loewe Additivity Score: 1.04
LHighest Single Agent (HSA) Score: 0.88

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Hepzato
Disease Entry ICD 11 Status REF
Uveal Melanoma 2D0Y Phase 3 [2]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Clear cell renal cell carcinoma DC837P2 786-0 Investigative [4]
Invasive ductal carcinoma DC4NK4W BT-549 Investigative [5]
Cutaneous melanoma DCXLI4K SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCHGV5M OVCAR-5 Investigative [1]
High grade ovarian serous adenocarcinoma DCBOFN4 OVCAR-8 Investigative [1]
High grade ovarian serous adenocarcinoma DCWX2JC NCI\\/ADR-RES Investigative [1]
Melanoma DC5Y0IP UACC-257 Investigative [1]
Melanoma DCHSWIB SK-MEL-2 Investigative [1]
Melanoma DCZMWMO MALME-3M Investigative [1]
Ovarian serous cystadenocarcinoma DCNNUUT SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.